JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

JNJ

233.69

+2.09%↑

ISRG

480.13

-3.45%↓

ABT

108.82

-0.38%↓

RDY

13.8

+2.45%↑

NEOG

10.27

-1.53%↓

Начало・Списък с акции・Vir Biotechnology Inc

Vir Biotechnology Inc

Отворен

СекторЗдравеопазване

7.57 -2.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.44

Максимум

7.93

Ключови измерители
By Trading Economics
Приходи	-52M -163M
Продажби	-974K 240K
Марж на печалбата	-67,975.417
Служители	408
EBITDA	-42M -160M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+124.6% upside

Дивиденти
By Dow Jones
Следващи печалби	25.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	259M 1B
Предишно отваряне	9.89
Предишно затваряне	7.57

Настроения в новините

By Acuity

50%

147 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 6.295 Подкрепа & съпротива

Vir Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2.02.2026 г., 23:28 ч. UTC

Пазарно говорене

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2.02.2026 г., 23:23 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2.02.2026 г., 22:57 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2.02.2026 г., 21:51 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.02.2026 г., 21:49 ч. UTC

Печалби

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2.02.2026 г., 21:39 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:36 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2.02.2026 г., 21:34 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 21:23 ч. UTC

Печалби

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2.02.2026 г., 21:19 ч. UTC

Печалби

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:10 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:08 ч. UTC

Печалби

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2.02.2026 г., 21:07 ч. UTC

Печалби

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Net $608.7M >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Rev $1.41B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Adj EPS 25c >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q EPS 24c >PLTR

2.02.2026 г., 20:40 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Vir Biotechnology Inc Прогноза

Ценова цел

By TipRanks

124.6% нагоре

12-месечна прогноза

Среден 16.71 USD 124.6%

Висок 31 USD

Нисък 12 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Vir Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Vir Biotechnology Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 6.295Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

147 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.